SCHEMBL21144248

SCHEMBL21144248

Cc1cc(C)n(-c2cccc(N(C)C3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
TSHR P16473 3/20 0.35
HSD17B10 Q99714 2/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
ALOX15 P16050 2/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
ACACB O00763 3/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ADORA2A P29274 2/20 0.34
ADORA1 P30542 2/20 0.34
CYP3A4 P08684 1/20 0.34
PTPN11 Q06124 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686607 0.79 SMN1; SMN2 (0.33) MAPTTSHRLMNAGAAALOX15
SCHEMBL19686280 0.76 MAPT (0.50) MAPTTSHRLMNAGAAALOX15
SCHEMBL19687387 0.71 ALOX15 (0.44) MAPTLMNAGAAALOX15SMN1; SMN2
SCHEMBL38661515 0.71 MAPT (0.77) MAPTTSHRHSD17B10LMNAGAA
SCHEMBL19686294 0.70 SMN1; SMN2 (0.42) MAPTTSHRHSD17B10LMNAGAA
SCHEMBL19686365 0.68 IDH1 (0.48) MAPTTSHRSMN1; SMN2
SCHEMBL21144052 0.67 MEN1 (0.46) MAPTTSHRHSD17B10KDM4EMEN1
SCHEMBL19686296 0.67 LMNA (0.48) MAPTTSHRLMNAGAAALOX15
SCHEMBL3574444 0.67 MAPT (1.00) MAPTTSHRHSD17B10LMNAGAA
SCHEMBL19686609 0.66 KCNN2 (0.41) MAPTTSHRHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 MAPT 2009/4885TSHR 2599/4885HSD17B10 1483/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 MAPT 2009/4885TSHR 2599/4885HSD17B10 1483/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 MAPT 2009/4885TSHR 2599/4885HSD17B10 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.